



Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial

Imre Noth, Vincent Cottin, Nazia Chaudhuri, Tamera J Corte, Kerri A Johannson, Marlies Wijsenbeek, Stephane Jouneau, Andreas Michael, Manuel Quaresma, Klaus B Rohr, et al.

► To cite this version:

Imre Noth, Vincent Cottin, Nazia Chaudhuri, Tamera J Corte, Kerri A Johannson, et al.. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. *European Respiratory Journal*, 2021, 58 (1), pp.2001518. 10.1183/13993003.01518-2020 . hal-03134370

HAL Id: hal-03134370

<https://hal.science/hal-03134370>

Submitted on 8 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Early View

Original article

Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial

Imre Noth, Vincent Cottin, Nazia Chaudhuri, Tamera J Corte, Kerri A Johansson, Marlies Wijsenbeek, Stephane Jouneau, Andreas Michael, Manuel Quaresma, Klaus B Rohr, Anne-Marie Russell, Susanne Stowasser, Toby M Maher

Please cite this article as: Noth I, Cottin V, Chaudhuri N, *et al.* Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. *Eur Respir J* 2021; in press (<https://doi.org/10.1183/13993003.01518-2020>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial

Imre Noth,¹ Vincent Cottin,² Nazia Chaudhuri,³ Tamera J Corte,⁴ Kerri A Johannson,⁵ Marlies Wijssenbeek,⁶ Stephane Jouneau,⁷ Andreas Michael,⁸ Manuel Quaresma,⁹ Klaus B Rohr,⁹ Anne-Marie Russell,¹⁰ Susanne Stowasser,⁹ Toby M Maher¹¹ on behalf of the INMARK trial investigators

¹Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia, USA; ²National Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France; ³North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, UK; ⁴Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia and University of Sydney, New South Wales, Australia; ⁵Medicine & Community Health Sciences, University of Calgary, Calgary, Canada; ⁶Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands; ⁷Hôpital Pontchaillou - CHU de Rennes, IRSET UMR 1085, Université de Rennes 1, Rennes, France; ⁸Syneos Health, Farnborough, UK; ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; ¹⁰College of Medicine and Health University of Exeter, UK; ¹¹National Heart and Lung Institute, Imperial College London, UK, National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Corresponding author:

Prof Toby M Maher
National Heart and Lung Institute
Imperial College
London
UK
Email: t.maher@rbht.nhs.uk

Abstract

Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).

Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12 weeks followed by open-label nintedanib for 40 weeks. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Subjects were asked to perform home spirometry at least once a week and ideally daily. Correlations between home- and clinic-measured FVC and rates of change in FVC were assessed using Pearson correlation coefficients.

In total, 346 subjects were treated. Mean adherence to weekly home spirometry decreased over time but remained above 75% in every 4-week period. Over 52 weeks, mean adherence was 86%. Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry. Strong correlations were observed between home- and clinic-measured FVC at all time-points ($r=0.72$ to 0.84), but correlations between home- and clinic-measured rates of change in FVC were weak ($r=0.26$ for rate of decline in FVC over 52 weeks).

Home spirometry was a feasible and valid measure of lung function in patients with IPF and preserved FVC, but estimates of the rate of FVC decline obtained using home spirometry were poorly correlated with those based on clinic spirometry.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease (ILD) characterised by decline in lung function [1]. Although IPF is always progressive, the rate and pattern of forced vital capacity (FVC) decline are variable among individuals [1–3]. Lung function has traditionally been measured periodically in a clinic-based setting, supervised by trained clinicians, but measurements obtained at home using a hand-held device have been shown to correlate well with clinic-based measurements over a 3–12-month period [4–8]. Home spirometry may offer advantages over clinic spirometry by increasing convenience for patients and providing more frequent measurements of lung function, enabling earlier detection of disease progression or acute exacerbations [4,6,9]. More frequent assessment of lung function via home spirometry might also provide improved analytical sensitivity, reducing the sample size required to power clinical trials [6]. However, in a recent trial conducted in subjects with unclassifiable ILD, the pre-specified analysis model could not be applied to the home spirometry measurements, in part due to issues with the reliability of the measurements [10]. More data are needed on the utility of home spirometry in the monitoring of lung function both in clinical trials and clinical practice.

In the INMARK trial in subjects with IPF and preserved lung function, lung function was assessed using both home and clinic spirometry over 52 weeks [11]. We used data from the INMARK trial to assess the feasibility and validity of home spirometry as a measure of lung function decline in subjects with IPF.

Methods

Study design and subjects

The primary objective of the INMARK trial was to investigate the effects of nintedanib on circulating biomarkers. The trial design has been described [11]. Briefly, subjects who had been diagnosed with IPF in the previous 3 years and had a forced vital capacity (FVC) $\geq 80\%$ predicted were randomised 1:2 to receive nintedanib 150 mg bid or placebo for 12 weeks, followed by an open-label period in which all subjects received nintedanib 150 mg bid for 40 weeks [11]. Home spirometry devices (SpiroPro[®]) and instructions were given to subjects at screening. To be eligible for the trial, subjects were required to perform ≥ 1 home spirometry reading between screening and randomisation (a period of ≤ 28 days). The last measurement taken prior to the first intake of nintedanib or placebo was used as the baseline measurement.

Home and clinic spirometry

Subjects were asked to perform home spirometry (with ≥ 3 efforts) at least once a week, and ideally daily, throughout the trial. The highest value of the ≥ 3 efforts was recorded as the measurement. Subjects were asked to perform home spirometry in the morning, preferably between 08:00 and 11:00. An acoustic alarm on the device was activated daily at 09:00 and 09:30 if the subject had not completed ≥ 1 effort. For every measurement, the device showed the subject their highest value for FVC % predicted (calculated according to [12]) and informed them if they had experienced a relative decline in FVC $\geq 10\%$ predicted from baseline; in this instance, subjects were advised to call their doctor. At each visit, subjects were re-trained on how to perform home spirometry if their adherence to weekly home spirometry since the last visit was $< 80\%$, or as deemed necessary by the site. Adherence to weekly home spirometry was calculated as the number of weeks that a subject provided ≥ 1 measurement divided by the number of weeks that they were followed in the trial. Thus 100% adherence was defined as provision of ≥ 1 measurement per week for all the weeks that the subject was in the trial.

Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Clinic spirometry was centrally reviewed, and ongoing feedback and training were provided to the sites.

Analyses

Correlations between the following assessments at every time point were assessed using Pearson correlation coefficients (r): home and clinic measurements of FVC (mL) and the forced expiratory volume in 6 seconds (FEV_6) (mL), home and clinic measurements of changes from baseline in FVC (mL) and FEV_6 (mL), and home and clinic measurements of rates of decline in FVC (mL) and FEV_6 (mL). In the analysis of correlations, the home measurement performed closest to the clinic visit was used (but the home spirometry device did not capture a measurement on the same day as a clinic visit).

The annual rates of decline in FVC and FEV_6 were assessed using random coefficient piecewise regression with fixed effects for sex, age, height and random effects of patient-specific intercept, time and a piecewise knot at week 12. Acute exacerbations, defined as in the INPULSIS trials [13], were reported by investigators using a tick box on the case report form and were not adjudicated. In subjects who had an investigator-reported acute exacerbation, all available home and clinic measurements of FVC (mL) before and after the acute exacerbation were plotted. Analyses were conducted using SAS[®]. Analyses were descriptive and exploratory.

Results

A total of 346 subjects were treated in the INMARK trial (116 randomised to nintedanib, 230 randomised to placebo). At baseline, mean (SD) FVC was 3305 (1060) mL and 99.6 (23.8) % predicted based on home spirometry and 3241 (812) mL and 97.5 (13.5) % predicted based on clinic spirometry. In total, 83.5% of the subjects who were randomised completed 52 weeks of treatment.

Annual rate of decline in FVC and FEV₆

In subjects treated with nintedanib for 52 weeks, adjusted mean (SE) home- and clinic-measured rates of FVC decline were -127.2 (76.3) and -88.8 (23.9) mL/year, respectively, and the adjusted mean (SE) home- and clinic-measured rates of FEV₆ decline were -112.6 (69.5) and -90.5 (22.3) mL/year, respectively. In subjects treated with placebo for 12 weeks followed by nintedanib for 40 weeks, adjusted mean (SE) home- and clinic-measured rates of FVC decline were -111.8 (54.7) and -104.1 (17.0) mL/year, respectively, and the adjusted mean (SE) home- and clinic-measured rates of FEV₆ decline were -131.8 (49.9) and -103.9 (15.9) mL/year, respectively.

Adherence to home spirometry

Over 52 weeks, the mean (SD) number of home spirometry measurements per subject was 165 (115) (Table 1). The mean (SD) number of measurements per subject per week was 3.4 (2.6) and the median was 3.0. The mean number of measurements per subject per week decreased over the trial but remained above 2.5 in every 4-week period (Figure 1).

Over 52 weeks, mean and median adherence to weekly home spirometry were 86% and 96%. Mean adherence to weekly home spirometry decreased over the trial but remained above 75% in every 4-week period (Figure 2a). The proportion of subjects with 100% adherence decreased over the trial but remained above 50% in every 4-week period (Figures 2b and S1). Over 52 weeks, 31% of subjects had 100% adherence to weekly home spirometry.

Subjects who had 100% adherence to weekly home spirometry (n=108) had slightly higher mean FVC and DLco at baseline than subjects who had <100% adherence (n=238) (Table S1). Permanent discontinuation of trial medication was less common among subjects with 100% versus <100% adherence to weekly home spirometry (4.6% versus 21.8%).

Timing of home spirometry measurements

Over 52 weeks, 45.7% of subjects provided only one measurement on any day on which they provided a measurement. Most subjects took some of their measurements in the morning (defined as between 05:00 and 12:00) and some in the afternoon/evening (defined as between 12:00 and 05:00) (Figure S2 and S3). Mean (SD) FVC at baseline was similar between measurements taken in the morning and the afternoon/evening (3379 [1062] mL and 3344 [1277] mL, respectively). Mean FVC over time was variable, with greater variability in the measurements taken in the afternoon/evening than in the morning (Figure S4).

Correlations between FVC and FEV₆ measured using home and clinic spirometry

Correlations between FVC and FEV₆, and changes in FVC and FEV₆, measured using home and clinic spirometry are presented in Figures 3a–c. Strong correlations were observed between home and clinic measurements of FVC ($r=0.72$ to 0.84), home and clinic measurements of FEV₆ ($r=0.71$ to 0.85), and clinic measurements of FVC and home measurements of FEV₆ ($r=0.71$ to 0.84) at all individual time points (Figure 3a). Correlations between home and clinic measurements of FVC were weaker in subjects who provided >3 versus ≤ 3 home spirometry measurements per week ($r=0.63$ to 0.75 versus $r=0.78$ to 0.94).

The variability in change from baseline in FVC was greater when measured using home spirometry than clinic spirometry (Figure 4). Correlations between home- and clinic-measured changes from baseline in FVC were weak but increased over 52 weeks ($r=-0.01$ at week 4 and $r=0.25$ at week 52). Similar correlations were observed for FEV₆ ($r=-0.01$ at week 4 and $r=0.27$ at week 52) (Figure 3b).

Correlations between home- and clinic-measured rates of change in FVC were weak but increased over 52 weeks ($r=0.00$ and $r=0.26$ for rates of decline in FVC over 4 and 52 weeks). Similar correlations were observed for rates of change in FEV₆ ($r=-0.05$ and $r=0.29$ over 4 and 52 weeks) (Figure 3c).

Home and clinic spirometry in subjects who had an acute exacerbation

One subject in the nintedanib group had an acute exacerbation during the double-blind period and seven subjects who initially received placebo had an acute exacerbation during the nintedanib open-label period. Home and clinic measurements of FVC before and after these acute exacerbations are presented in Figure S5.

Discussion

In the INMARK trial conducted in subjects with IPF and preserved lung function, adherence to weekly home spirometry over 52 weeks was over 75% in every 4-week period, but

decreased over time. Over 52 weeks, 31% of subjects adhered to the request to provide at least one measurement per week for all the weeks they were in the trial. A proportion of subjects provided more measurements than the minimum requested, with an average of three measurements per subject per week. These findings are consistent with previous studies in patients with ILDs that have demonstrated high adherence to daily or weekly home spirometry, but with high variability among individuals and a reduction in the number of measurements provided over time [6,8,14]. Previous work suggests that patients with IPF find home spirometers easy to use and not burdensome, and that patients like to see their FVC results to feel more in control of their disease [6,15,16]. A study of 30 subjects found that only four were unable to use the home spirometry device [6].

Within-subject variability in FVC measurements taken day-to-day or week-to-week has been observed in healthy individuals [17] as well as in subjects with IPF [4,6]. The literature is inconsistent with respect to diurnal variations in FVC; several studies have found FVC to be generally higher in the morning than in the afternoon [18–20], but this has not been observed in all studies [21]. In the INMARK trial, subjects were asked to perform spirometry in the morning, but fewer than a third of subjects adhered to this request. The mean of FVC measurements taken in the morning was almost the same as the mean of measurements taken in the afternoon/evening, but, consistent with a previous study [20], variability appeared to be greater in measurements taken in the afternoon/evening than in the morning.

Consistent with previous studies [4,6–8,15,16], we found that home and clinic measurements of FVC at individual visits were strongly correlated. However, there was only a weak correlation between home- and clinic-based measurements of changes in FVC. This appeared to be largely due to variability in changes in FVC measured using home spirometry, which was much greater than the variability observed using clinic spirometry. Errors in measurements taken at different time points accumulate, such that measurement error has a greater impact on assessments of changes in FVC over time, which are based on several measurements, than on measurements taken at single time points. While it may be hypothesised that more frequent home spirometry (i.e., more data points) might provide a more accurate estimate of lung function, in our study, correlations between home and clinic measurements of FVC were weaker in subjects who provided more spirometry measurements per week, likely due to a greater number of outliers. This was observed despite the home spirometry device selecting the highest of three readings for every measurement. Improving the accuracy of home-based spirometry might overcome this problem. To date, no head-to-head comparisons of different spirometers have been undertaken to assess whether particular devices are easier to use correctly and associated with lower measurement error. The correlations between home- and clinic-measured FVC at

baseline and at week 52 were the same, suggesting that there was no increase in the reliability of home spirometry during the trial. It has been proposed that the abbreviated FEV₆ manoeuvre may be easier for patients to perform than measurement of FVC and so improve reproducibility among unsupervised subjects [22]. However, in our analyses, the correlations between home and clinic measurements of FVC were almost the same as the correlations between home and clinic measurements of FEV₆.

It has been postulated that more frequent measurement of FVC at home might enable earlier detection of an acute exacerbation. In a pilot study performed in 10 subjects, a decline in FVC based on daily home spirometry was observed 2 days before symptoms of a respiratory tract infection [15]. We were unable to perform a robust investigation into whether acute exacerbations could be detected earlier using more frequent home spirometry using our data given the small number of acute exacerbations reported in this population with very well preserved FVC at baseline and the low frequency of home spirometry measurements around the time of acute exacerbations.

Although not observed in the INMARK trial, technical issues with home spirometry devices and analytical issues arising from missing data have affected the analysis of home spirometry data from clinical studies in patients with ILDs [23], including trials of potential new therapies [10, 24]. More data are needed to inform strategies to ensure the quality of readings and reduce the variability of measurements obtained using home spirometry by better educating and motivating patients on the use of spirometry devices. It might be possible to reduce the amount of missing data and the variability of home spirometry measurements via local support from nurses or other healthcare professionals, or via closer or more regular examination of data so that any issues can be addressed promptly with the patient. A recent 24-week study in 90 patients with IPF that investigated the utility of a home monitoring programme integrating daily home spirometry, patient-reported outcomes, adverse event reporting, an information library and electronic consultations, found home spirometry to be a reliable and accurate way of monitoring FVC [16]. Median adherence to daily home spirometry over 24 weeks was high (97%) and correlations between home- and hospital-based measurements of FVC were strong at all time points. Unlike in the INMARK trial, in this study, correlation between the rates of change in home- and hospital-based measurements of FVC was moderately strong ($r=0.58$) [16].

Strengths of our analyses include the prospective multi-centre design and the high frequency and volume of clinic and home spirometry measurements collected. Our findings also have limitations, including selection bias in the subjects who participated in the study, all of whom had preserved lung function at baseline, had shown a degree of adherence to home spirometry before entering the study, and had chosen to enter a study that required home spirometry. We were unable to investigate whether comorbid asthma or COPD had an

impact on spirometry as so few patients in our study had these comorbidities. Our study did not collect data on subjects' opinions (positive or negative) of home spirometry or on the reasons behind adherence/non-adherence to home spirometry.

In conclusion, in patients with IPF and preserved lung function, adherence to weekly home spirometry decreased over 52 weeks but remained high. Strong correlations were observed between FVC measurements obtained at home and in clinic at individual time-points, but correlations between changes in FVC measurements over time estimated using home and clinic spirometry were weak, mainly due to variability in the measurements obtained using home spirometry. At a group level, the rate of decline in FVC over 52 weeks was similar when measured using home or clinic spirometry. More data are needed on the utility of home spirometry as a means of measuring disease progression in patients with IPF in clinical trials and clinical practice.

A video abstract describing the key data presented in this manuscript is available at: <https://www.globalmedcomms.com/respiratory/noth/homespirometry>

Funding statement

The INMARK trial was funded by Boehringer Ingelheim.

Acknowledgements

The authors thank the patients who participated in this trial. The authors did not receive payment for development of this manuscript. Writing assistance was provided by Julie Fleming and Wendy Morris of FleishmanHillard Fishburn, London, UK, which was contracted and funded by Boehringer Ingelheim. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.

Conflicts of interest

IN reports personal fees from Boehringer Ingelheim, Genentech and ImmuneWorks. VC reports grants, personal fees and non-financial support from Boehringer Ingelheim; personal fees and non-financial support from Actelion and Roche; and personal fees from Bayer/Merck Sharp & Dohme, Celgene, Galapagos NV, Galecto, Novartis, Promedior and Sanofi. NC reports grants, personal fees and other from Boehringer Ingelheim and Roche. TJC reports grants and personal fees from Boehringer Ingelheim, Bristol-Myers Squibb and Roche; grants from Bayer, Gilead and InterMune; and personal fees from AdAlta, AstraZeneca and Promedior. KJ reports personal fees and other from Blade Therapeutics, Boehringer Ingelheim, Hoffmann-La Roche, and Theravance Biopharma; grants from the CHEST Foundation, the Pulmonary Fibrosis Society of Calgary, UCB Biopharma SPRL, and

the University of Calgary School of Medicine; and other from Three Lakes Foundation. MW reports grants and fees paid to her institution from Boehringer Ingelheim and Hoffmann-La Roche; and fees paid to her institution from Galapagos NV and Respivant. SJ reports personal fees from Actelion, AIRB, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Galecto, Gilead, GlaxoSmithKline, LVL, Mundipharma, Novartis, Pfizer, Roche and Savara-Serendex. AM is a contractor to Boehringer Ingelheim. MQ, KBR and SS are employees of Boehringer Ingelheim. AMR reports grants and personal fees from Boehringer Ingelheim; grants from Action for Pulmonary Fibrosis, the Imperial Health Charity and Pulmonary Fibrosis Trust UK; and personal fees from Hoffmann-La Roche and the Irish Lung Fibrosis Association. TMM reports grants and personal fees from GlaxoSmithKline and UCB; and personal fees from Apellis, Bayer, Biogen, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos NV, Galecto, Indalo Therapeutics, Novartis, Respivent, Roche and Trevi.

References

1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med* 2018;198:e44–e68.
2. Doubková M, Švancara J, Svoboda M, Šterclová M, Bartoš V, Plačková M, Lacina L, Žurková M, Binková I, Bittenglová R, Lošťáková V, Merta Z, Šišková L, Tyl R, Lisá P, Šuldová H, Petřík F, Pšikalová J, Řihák V, Snížek T, Reiterer P, Homolka J, Musilová P, Lněnička J, Palúch P, Hrdina R, Králová R, Hortvíková H, Strenková J, Vašáková M. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. *Clin Respir J* 2018;12:1526–35.
3. Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, Hopkins P, Keir G, Mahar A, Cooper W, Reynolds P, Haydn Walters E, Zappala C, Grainge C, Allan H, Macansh S, Corte TJ. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. *BMC Pulm Med* 2018;18:19.

4. Russell AM, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, Wells AU, Maher TM. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2016;194:989–97.
5. Maher TM. Home spirometry for idiopathic pulmonary fibrosis: ready for prime time? *Eur Respir J* 2017;50(1). pii: 1701403. doi: 10.1183/13993003.01403-2017.
6. Johansson KA, Vittinghoff E, Morisset J, Lee JS, Balmes JR, Collard HR. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. *Eur Respir J* 2017;50(1).
7. Marcoux V, Wang M, Burgoyne SJ, Fell CD, Ryerson CJ, Sajobi TT, Johansson KA. Mobile health monitoring in patients with idiopathic pulmonary fibrosis. *Ann Am Thorac Soc* 2019;16:1327–29.
8. Swigris JJ, Nathan SD, Tighe RM, Nagra S, Rabe C, Kelkhoff D, Switzer T, Kolatkar N, Belloni P, Golden J. STARMAP: an observational study to assess disease-relevant outcomes using home monitoring devices in patients with idiopathic pulmonary fibrosis (IPF). Poster presented at the European Respiratory Society International Congress, Madrid, Spain, 28 September–2 October 2019.
9. Wijsenbeek M, Bendstrup E, Valenzuela C, Henry MT, Moor C, Bengus M, Perjesi A, Gilberg F, Kirchgaessler KU, Vancheri C. Design of a study assessing disease behaviour during the peri-diagnostic period in patients with interstitial lung disease: the STARLINER Study. *Adv Ther* 2019a;36:232–43.
10. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Respir Med* 2020;8:147–157.
11. Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG; INMARK trial investigators. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. *Lancet Respir Med* 2019;7:771–79.
12. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;16:5–40.

13. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS trial investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med* 2014;370:2071–82.
14. Wijsenbeek MS, Bendstrup E, Valenzuela C, Henry MT, Moor C, Jouneau S, Fois A, Moran O, Anees S, Mirt M, Bengus M, Gilberg F, Kirchgaessler KU, Vancheri C. Interim analysis of patients with ILD enrolled in the STARLINER study. Poster presented at the European Respiratory Society International Congress, Madrid, Spain, 28 September–2 October 2019b.
15. Moor CC, Wapenaar M, Miedema JR, Geelhoed JJM, Chandoesing PP, Wijsenbeek MS. A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers. *Respir Res* 2018;19:105.
16. Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Chavannes NH, Wijsenbeek MS. Home monitoring in patients with idiopathic pulmonary fibrosis. a randomized controlled trial. *Am J Respir Crit Care Med* 2020;202:393–401.
17. Rozas CJ and Goldman AL. Daily spirometric variability: normal subjects and subjects with chronic bronchitis with and without airflow obstruction. *Arch Intern Med* 1982;142:1287-91.
18. Borsboom GJ, van Pelt W, van Houwelingen HC, van Vianen BG, Schouten JP, Quanjer PH. Diurnal variation in lung function in subgroups from two Dutch populations: consequences for longitudinal analysis. *Am J Respir Crit Care Med* 1999;159:1163–71.
19. Fregonezi G, Resqueti VR, Cury JL, Paulin E, Brunetto AF. Diurnal variations in the parameters of pulmonary function and respiratory muscle strength in patients with COPD. *J Bras Pneumol* 2012;38:257–63.
20. Moor CC, van den Berg CAL, Visser LS, Aerts JGJV, Cottin V, Wijsenbeek MS. Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. *ERJ Open Res* 2020;6:00054-2020.
21. Medarov BI, Pavlov VA, Rossoff L. Diurnal variations in human pulmonary function. *Int J Clin Exp Med* 2008;1:267–73.
22. Vandevoorde J, Verbanck S, Schuermans D, Kartounian J, Vincken W. FEV1/FEV6 and FEV6 as an alternative for FEV1/FVC and FVC in the spirometric detection of airway obstruction and restriction. *Chest* 2005;127:1560-4.

23. Maher TM, Swigris J, Moor C, Bengus M, Axmann J, Belloni P, Kirschgaessler KU, Wijsenbeek MS. Home spirometry as an endpoint in interstitial lung diseases clinical trials – lessons learned. Poster presented at the American Thoracic Society conference 2020.
24. Maher TM, Corte TJ, Kreuter M, Molina-Molina M, Axmann J, Gilberg F, Kirschgaessler KU, Cottin V. Home spirometry as a primary endpoint in clinical trials: sensitivity analyses of a randomized controlled trial of pirfenidone in patients with unclassifiable interstitial lung disease. Poster presented at the American Thoracic Society conference 2020.


Table

Table 1. Number of home spirometry measurements per subject over 52 weeks

	Nintedanib (n=116)	Placebo/nintedanib* (n=230)	All subjects (n=346)
Mean (SD)	157 (106)	170 (119)	165 (115)
Minimum	3	3	3
Median	125	136	132
Maximum	362	633	633

*Subjects received placebo (blinded) for 12 weeks followed by open-label nintedanib for 40 weeks.


Figure 1. Mean number of home spirometry measurements per subject per week



Analysis based on the total number of home spirometry measurements collected and the number of subjects who were still followed in the trial within the time period.


Figure 2. a) Mean adherence to weekly home spirometry and b) the proportion of subjects with 100% adherence to weekly home spirometry

a)



Adherence to weekly home spirometry was calculated as the number of weeks that a subject provided ≥ 1 measurement divided by the number of weeks that they were followed in the trial.


b)



100% adherence was defined as provision of ≥ 1 measurement per week for all the weeks that the subject was in the trial. The total number of subjects who were still followed in the trial within the time period was used as the denominator.


Figure 3. “Heat maps” depicting correlations between a) lung function variables measured at home and in clinic at different time points, b) changes from baseline in lung function variables measured at home and in clinic at different time points, and c) rates of decline in lung function variables measured at home and in clinic at different time points

a)



Darker shades of red denote stronger positive correlations. $r \geq 0.5$ for all correlations.

b)



Darker shades of red denote stronger positive correlations.

c)






Figure 4. Changes from baseline in FVC based on a) home spirometry and b) clinic spirometry

a)



b)



The crosses denote the mean values, the mid-line of the boxes the median values, and the boundaries of the boxes the 25th and 75th percentiles; the upper whiskers denote the values $1.5 \times$ the interquartile range above the 75th percentile, the lower whiskers denote the values $1.5 \times$ the interquartile range below the 25th percentile and the boxes denote values that fell outside the range of the whiskers.


Supplementary appendix

Table S1. Baseline characteristics of subjects with 100% and <100% adherence to weekly home spirometry

	100% adherence to weekly home spirometry (n=108)	<100% adherence to weekly home spirometry (n=238)
Age, years, mean (SD)	69.9 (7.3)	70.5 (7.4)
Male, n (%)	84 (77.8)	178 (74.8)
Race, n (%)		
White	59 (54.6)	155 (65.1)
Asian	35 (32.4)	68 (28.6)
Missing	14 (13.0)	15 (6.3)
Weight, kg, mean (SD)	79.2 (17.0)	76.9 (15.4)
Body mass index, kg/m ² , mean (SD)	27.8 (4.5)	27.2 (4.1)
Former or current smoker, n (%)	81 (75.0)	171 (71.8)
FVC, mL, mean (SD)	3333 (785)	3200 (822)
FVC, % predicted, mean (SD)	99.2 (15.0)	96.8 (12.8)
DLco*, % predicted, mean (SD)	69.8 (21.2)	61.3 (18.6)

100% adherence was defined as the provision of ≥ 1 measurement per week for all the weeks the subject was in the trial. *Corrected for haemoglobin.


Figure S1. Proportion of subjects with 100% adherence to home spirometry by treatment group



100% adherence was defined as provision of ≥ 1 measurement per week for all the weeks that the subject was in the trial. The total number of subjects who were still followed in the trial within the time period was used as the denominator.


*Subjects received placebo (blinded) for 12 weeks followed by open-label nintedanib for 40 weeks.

Figure S2. Timing of home spirometry among subjects who provided only one measurement in a given day



Morning measurements were taken between 05:00 and 12:00 (inclusive). Afternoon/evening measurements were taken after 12:00 and before 05:00.
*Subjects received placebo (blinded) for 12 weeks followed by open-label nintedanib for 40 weeks.

Figure S3. Timing of home spirometry among subjects who provided multiple measurements on at least 1 day




The number of subjects who provided multiple measurements on at least 1 day was used as the denominator.

Morning measurements were taken between 05:00 and 12:00 (inclusive). Afternoon/evening measurements were taken after 12:00 and before 05:00.


*Subjects received placebo (blinded) for 12 weeks followed by open-label nintedanib for 40 weeks.

Figure S4. FVC (mL) based on home spirometry measured in the morning and the afternoon/evening




*Subjects received placebo (blinded) for 12 weeks followed by open-label nintedanib for 40 weeks.
Morning measurements were taken between 05:00 and 12:00 (inclusive). Afternoon/evening measurements were taken after 12:00 and before 05:00.

Figure S5. Clinic- and home-measured FVC (mL) over time in subjects initially randomised to nintedanib (a) or placebo (b–g) who had an acute exacerbation




c)

Clinic spirometry




Home spirometry




d)

Clinic spirometry




Home spirometry




e)

Clinic spirometry




Home spirometry




f)



Clinic spirometry



Home spirometry



g)



h)

